[HTML][HTML] Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

PF Robbins, RA Morgan, SA Feldman… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
PF Robbins, RA Morgan, SA Feldman, JC Yang, RM Sherry, ME Dudley, JR Wunderlich…
Journal of Clinical Oncology, 2011ncbi.nlm.nih.gov
Purpose Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an
effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1
cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and
approximately 25% of patients with melanoma and common epithelial tumors, represents an
attractive target for immune-based therapies. The current trial was carried out to evaluate the
ability of adoptively transferred autologous T cells transduced with a T-cell receptor (TCR) …
Abstract
Purpose
Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and approximately 25% of patients with melanoma and common epithelial tumors, represents an attractive target for immune-based therapies. The current trial was carried out to evaluate the ability of adoptively transferred autologous T cells transduced with a T-cell receptor (TCR) directed against NY-ESO-1 to mediate tumor regression in patients with metastatic melanoma and synovial cell sarcoma.
ncbi.nlm.nih.gov